Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study.
about
Multiple sclerosisSystematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Lower Limb SpasticityPharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.Ixcellence Network®: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection.Botulinum toxin A (BoNT-A) for spasticity in adults. What is the evidence?Treating pain in multiple sclerosis.Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.Symptomatic therapy and rehabilitation in primary progressive multiple sclerosisThe beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles.Symptomatic management and rehabilitation in multiple sclerosis.Botulinum toxin in clinical practiceTreatment of children and adolescents with multiple sclerosis.Treatment of symptoms in multiple sclerosis.A mechanism-based classification of pain in multiple sclerosis.Botulinum toxin type A combined with neurodynamic mobilization for lower limb spasticity: a case reportBotulinum toxin A in the overactive bladder: current status and future directions.The role of botulinum toxin injections in the management of muscle overactivity of the lower limb.Cannabinoids in the management of spasticity associated with multiple sclerosis.Botulinum toxin treatment of adult spasticity.Botulinum toxin A (Dysport®): in dystonias and focal spasticity.Rehabilitation interventions in multiple sclerosis: an overview.Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence.The efficacy of Botulinum Toxin A for spasticity and pain in adults: a systematic review and meta-analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach.Botulinum toxin for neuropathic pain and spasticity: an overview.Botulinum toxin for symptomatic therapy in multiple sclerosis.The efficacy of Botulinum Toxin A on improving ease of care in the upper and lower limbs: a systematic review and meta-analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach.The efficacy of Botulinum Toxin A for limb spasticity on improving activity restriction and quality of life: a systematic review and meta-analysis using the GRADE approach.Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study.Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.Relationship Between Botulinum Toxin, Spasticity, and Pain: a Survey of Patient Perception.Neurologic uses of botulinum neurotoxin type A.Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients.Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis? A single-blind randomized controlled trial.Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia--report of 19 cases.Botulinum toxin injection in patients with hereditary spastic paraparesis.Botulinum toxin to treat upper-limb spasticity in hemiparetic patients: analysis of function and kinematics of reaching movements.A randomized controlled trial of botulinum toxin on lower limb spasticity following acute acquired severe brain injury.Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up.Intramuscular nerve distribution pattern of the adductor longus and gracilis muscles demonstrated with Sihler staining: guidance for botulinum toxin injection.
P2860
Q26995437-34395556-2FB0-4FF6-891C-17AFD7905560Q28074221-AB69977E-63F2-44E2-BE2D-6787FF87B52DQ30250250-9EB13037-FB58-46C3-B087-60AD65F8050EQ33897459-74827848-9A3D-4B12-BCAC-47C5B8FDF298Q34579725-0E863629-D944-4375-881B-625DC47040F2Q34632301-D7ECEBB4-B93C-4D4F-8CBC-A10C0942ADAEQ35018491-D3795A1A-79BD-4A15-B4D4-642FCF190B90Q35377529-83894C16-3C0E-4E1A-8AE2-50849240336FQ35477882-923F6EF4-4E22-4FB0-AC66-5A0E0F825253Q35576298-86C381ED-5005-4C8A-BF7B-51A205A56469Q35807826-110ABA95-5BEC-4790-8644-64D0E588EE0BQ36153390-F886F3E8-CC44-41E8-966E-9078BC31BADBQ36474348-FD15CB1D-5776-4895-98E4-CFCFAE519525Q36592669-33BD4A43-AAF8-4C51-9070-3D7AF58CEA6CQ36724869-D13B6D37-2A26-4E20-A782-574BA61502EDQ36741471-EB93CA86-B47A-4DDD-A1A2-6A2D9AD507DBQ37011519-87D27CA6-363A-4087-A3E0-2A4286D359E0Q37062594-4B9C7804-F9B1-462A-A590-404C906079F2Q37610190-30476783-8137-47C4-B397-63B6C47FD49DQ37888668-BD1128D2-994C-4683-BC93-06BA25F0921AQ38024650-834EA938-DA2A-4253-BF36-696DB39172EEQ38098126-2BF1D8C6-A6B8-4070-B9E1-0702A3A392B0Q38122349-70078CCD-6453-4AFF-8C2B-CB4F7CE381D1Q38196928-50A0758F-3475-4B2C-8B62-C4AEC3C687FDQ38222194-169F4285-2B6B-4830-B0AD-1802F31BACAEQ38263487-E617E604-7E2D-4F8D-8C9C-CD7C9D964813Q38543439-9713BE12-76B2-4959-A2BE-5908F492C05DQ38647620-CDE3568C-34C6-4561-9488-D01B2CB8E589Q38992567-AC500E8C-43AD-4699-A04E-093D1E50A0C2Q39178945-C85B09A3-34BF-4195-AD00-D48868ABAF22Q42086848-0CF4EDCB-845E-49B4-8E8A-C8B826DD39DEQ44608563-159E1A18-3F33-40CC-B7B1-7458E2306CEBQ45354993-11D30F93-95CB-4E40-ACF9-9607EA034398Q46894101-FF41E3CA-5389-4C80-992E-F69A99AE6E08Q46902454-E7727D42-CBCF-48D4-87BC-C0557C59E2C7Q47815397-3E4A1F89-F9AD-4B8C-B7C3-F7A7CF5821ADQ48347693-2A7FB6A8-F977-4B8F-A9FE-D74C9DC6AA35Q48974151-D41D6A79-3434-42BB-A683-A1BFA9AA93D1Q51381155-B586C889-F65A-4C6C-B83C-18B6CD7CEF1EQ51777592-DC077CBB-A9D8-4C36-A3C6-A264699EDD37
P2860
Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Botulinum toxin (Dysport) trea ...... ontrolled, dose ranging study.
@ast
Botulinum toxin (Dysport) trea ...... ontrolled, dose ranging study.
@en
type
label
Botulinum toxin (Dysport) trea ...... ontrolled, dose ranging study.
@ast
Botulinum toxin (Dysport) trea ...... ontrolled, dose ranging study.
@en
prefLabel
Botulinum toxin (Dysport) trea ...... ontrolled, dose ranging study.
@ast
Botulinum toxin (Dysport) trea ...... ontrolled, dose ranging study.
@en
P2093
P2860
P356
P1476
Botulinum toxin (Dysport) trea ...... ontrolled, dose ranging study.
@en
P2093
Glickman S
Kreczy-Kleedorfer B
Richardson A
P2860
P304
P356
10.1136/JNNP.68.6.707
P407
P50
P577
2000-06-01T00:00:00Z